Table 2.
Based on intervention treatment, control treatment and treatment duration of subgroup analysis.
| Variables | Clinical score | Clinical resolution | Total lesion size | |||
|---|---|---|---|---|---|---|
| Overall estimate (95% CI) | p-value | Overall estimate (95% CI) | p-value | Overall estimate (95% CI) | p-value | |
| Intervention treatment | ||||||
| 20 ug/patch CLO | −0.20 (−0.58, 0.18) | 0.308 | NA | NA | −2.37 (−7.43, 2.69) | 0.359 |
| 5 ug/patch CLO | −0.10 (−0.50, 0.30) | 0.621 | NA | NA | −1.08 (−5.73, 3.57) | 0.649 |
| 1 ug/patch CLO | 0.10 (−0.25, 0.45) | 0.577 | NA | NA | −1.99 (−6.93, 2.95) | 0.430 |
| 0.05% CLO | 0.27 (−0.45, 0.98) | 0.462 | 1.53 (1.12, 2.11) | 0.009 | −0.55 (−1.00, −0.09) | 0.018 |
| 0.025% CLO | NA | NA | 3.16 (1.00, 9.93) | 0.049 | NA | NA |
| Control treatment | ||||||
| PBO | −0.10 (−0.31, 0.10) | 0.306 | 3.25 (0.33, 31.81) | 0.311 | −1.77 (−4.59, 1.04) | 0.217 |
| TAC | 0.09 (−0.16, 0.34) | 0.487 | 1.04 (0.81, 1.33) | 0.777 | −0.02 (−1.61, 1.57) | 0.982 |
| CYC | NA | NA | 3.16 (1.00, 9.93) | 0.049 | NA | NA |
| FLU | NA | NA | 3.00 (1.35, 6.68) | 0.007 | NA | NA |
| TRI | NA | NA | 2.82 (1.25, 6.40) | 0.013 | NA | NA |
| MES | NA | NA | NA | NA | NA | NA |
| AIM | NA | NA | 2.41 (1.16, 4.99) | 0.018 | NA | NA |
| Coconut | NA | NA | NA | NA | −0.19 (−1.79, 1.41) | 0.816 |
| N. sativa | NA | NA | NA | NA | −0.63 (−1.13, −0.14) | 0.012 |
| PDT | 1.14 (1.00, 1.28) | <0.001 | 1.18 (0.76, 1.83) | 0.456 | NA | NA |
| Treatment duration | ||||||
| 4 weeks | −0.06 (−0.27, 0.16) | 0.617 | 1.18 (0.76, 1.83) | 0.456 | −0.58 (−1.97, 0.82) | 0.416 |
| 5 weeks | 0.07 (−0.19, 0.33) | 0.576 | NA | NA | NA | NA |
| 6 weeks | NA | NA | 1.24 (0.87, 1.75) | 0.231 | −0.58 (−1.03, −0.13) | 0.016 |
| 8 weeks | −0.40 (−0.93, 0.13) | 0.139 | 1.75 (0.86, 3.58) | 0.123 | NA | NA |
| 9 weeks | NA | NA | 2.82 (1.25, 6.40) | 0.013 | NA | NA |
| 12 weeks | 1.02 (0.48, 1.55) | <0.001 | 1.41 (0.57, 3.48) | 0.457 | NA | NA |
| 17 weeks | NA | NA | NA | NA | NA | NA |
| 26 weeks | NA | NA | 4.15(1.13, 15.25) | 0.032 | NA | NA |
| Variables | Pain score | Symptoms improvement | Adverse effects | |||
| Overall estimate (95% CI) | P-value | Overall estimate (95% CI) | P-value | Overall estimate (95% CI) | P-value | |
| Intervention treatment | ||||||
| 20 ug/patch CLO | −0.10 (−1.24, 1.04) | 0.864 | 2.13 (1.29, 3.53) | 0.003 | 0.94 (0.56, 1.58) | 0.814 |
| 5 ug/patch CLO | 0.10 (−1.00, 1.20) | 0.859 | NA | NA | 0.97 (0.58, 1.62) | 0.915 |
| 1 ug/patch CLO | 0.00 (−1.07, 1.07) | 1.000 | NA | NA | 0.88 (0.53, 1.47) | 0.619 |
| 123 ug/semisolid CLO | NA | NA | 3.67 (1.25, 10.71) | 0.018 | 13.00 (0.79, 213.09) | 0.072 |
| 24 ug/tablet CLO | NA | NA | 4.33 (1.52, 12.34) | 0.006 | NA | NA |
| 0.05% CLO | 0.22 (−0.52, 0.96) | 0.560 | 1.36 (0.77, 2.41) | 0.292 | 2.42 (0.61, 9.56) | 0.208 |
| 0.025% CLO | NA | NA | 2.11 (0.76, 5.86) | 0.154 | 6.32 (0.84, 47.69) | 0.074 |
| Control treatment | ||||||
| PBO | −0.24 (−0.92, 0.43) | 0.481 | 2.83 (1.81, 4.43) | <0.001 | 0.97 (0.72, 1.30) | 0.830 |
| TAC | 0.29 (0.05, 0.53) | 0.020 | 0.33 (0.04, 3.06) | 0.332 | 0.43 (0.01, 17.40) | 0.657 |
| CYC | NA | NA | 2.11 (0.76, 5.86) | 0.154 | 6.32 (0.84, 47.69) | 0.074 |
| FLU | NA | NA | 2.67 (1.32, 5.39) | 0.006 | 7.00 (0.38, 127.32) | 0.189 |
| TRI | NA | NA | 1.50 (0.95, 2.36) | 0.081 | NA | NA |
| MES | NA | NA | 1.05 (0.52, 2.12) | 0.897 | NA | NA |
| AIM | NA | NA | 2.22 (0.22, 22.49) | 0.499 | 13.00 (0.78, 216.39) | 0.074 |
| Coconut | 0.97 (0.04, 1.90) | 0.040 | NA | NA | NA | NA |
| N. sativa | −0.34 (−0.76, 0.08) | 0.113 | NA | NA | NA | NA |
| PDT | 0.78 (−2.05, 3.61) | 0.591 | NA | NA | 11.00 (0.65, 187.17) | 0.097 |
| Treatment duration | ||||||
| 4 weeks | 0.31 (−0.21, 0.84) | 0.243 | 2.20 (1.23, 3.95) | 0.008 | 0.92 (0.57, 1.49) | 0.738 |
| 5 weeks | 0.28 (0.04, 0.53) | 0.024 | NA | NA | NA | NA |
| 6 weeks | −0.29 (−0.70, 0.12) | 0.166 | 0.07 (0.00, 1.08) | 0.056 | NA | NA |
| 8 weeks | −1.80 (−3.53, −0.07) | 0.042 | 2.11 (0.76, 5.86) | 0.154 | 2.82 (1.10, 7.24) | 0.031 |
| 9 weeks | NA | NA | 1.50 (0.95, 2.36) | 0.081 | 7.00 (0.38, 127.32) | 0.189 |
| 12 weeks | 2.02 (1.69, 2.35) | <0.001 | 0.77 (0.48, 1.23) | 0.277 | 11.97 (1.63, 88.08) | 0.015 |
| 17 weeks | −0.90 (−3.13, 1.32) | 0.428 | NA | NA | NA | NA |
| 26 weeks | NA | NA | 3.23 (1.43, 7.34) | 0.005 | NA | NA |
NA, not available; CLO, clobetasol; PBO, placebo; N. sativa, Nigella sativa; AIM, Anti-Inflammatory Mouthwash; TAC, tacrolimus; PDT, photodynamic therapy; CYC, cyclosporin; FLU, fluocinonide; MES; mesalazine; TRI, triamcinolone.